Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma

Documenti analoghi

• Differential predictive value of tissue‐specific PD‐L1 expression scores in adjuvant immunotherapy of melanoma
  di: Glenn Geidel, et al.
  Pubblicazione: (2024)
• Age matters: Rethinking SLNB's reliability in melanoma mortality prediction
  di: Christoffer Gebhardt
  Pubblicazione: (2024)
• Revisiting the evidence: UV exposure, melanoma and the need for smarter public health strategies
  di: Efthymia Soura, et al.
  Pubblicazione: (2025)
• Bridging the gap: From clinical intuition to structured cutaneous squamous cell carcinoma classification
  di: Christoffer Gebhardt
  Pubblicazione: (2025)
• Cutaneous melanoma in adolescents and young adults
  di: Alessandra Buja, et al.
  Pubblicazione: (2024)